Cara Therapeutics Inc logo

Cara Therapeutics Inc

1
NAS:CARA (USA)  
$ 0.92 +0.0293 (+3.34%) 11:08 PM EST
At Loss
P/B:
0.86
Market Cap:
$ 50.39M
Enterprise V:
$ -47.53M
Volume:
337.49K
Avg Vol (2M):
796.02K
Also Trade In:
Volume:
337.49K
At Loss
Avg Vol (2M):
796.02K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Cara Therapeutics Inc ( ) from 2014 to Mar 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Cara Therapeutics stock (CARA) PE ratio as of Mar 19 2024 is 0. More Details

Cara Therapeutics Inc (CARA) PE Ratio (TTM) Chart

To

Cara Therapeutics Inc (CARA) PE Ratio (TTM) Historical Data

Total 1253
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Cara Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-26 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-16 At Loss 2023-12-12 At Loss
2024-02-15 At Loss 2023-12-11 At Loss
2024-02-14 At Loss 2023-12-08 At Loss
2024-02-13 At Loss 2023-12-07 At Loss
2024-02-12 At Loss 2023-12-06 At Loss
2024-02-09 At Loss 2023-12-05 At Loss
2024-02-08 At Loss 2023-12-04 At Loss
2024-02-07 At Loss 2023-12-01 At Loss
2024-02-06 At Loss 2023-11-30 At Loss
2024-02-05 At Loss 2023-11-29 At Loss
2024-02-02 At Loss 2023-11-28 At Loss
2024-02-01 At Loss 2023-11-27 At Loss
2024-01-31 At Loss 2023-11-24 At Loss
2024-01-30 At Loss 2023-11-22 At Loss
2024-01-29 At Loss 2023-11-21 At Loss
2024-01-26 At Loss 2023-11-20 At Loss
2024-01-25 At Loss 2023-11-17 At Loss
2024-01-24 At Loss 2023-11-16 At Loss
2024-01-23 At Loss 2023-11-15 At Loss
2024-01-22 At Loss 2023-11-14 At Loss
2024-01-19 At Loss 2023-11-13 At Loss
2024-01-18 At Loss 2023-11-10 At Loss
2024-01-17 At Loss 2023-11-09 At Loss
2024-01-16 At Loss 2023-11-08 At Loss

Cara Therapeutics Inc (CARA) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.